AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04612777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Description: Case Management (CM) services, as defined by the State mental health agency, consist of providing essential environmental support and care coordination to assist the individual with improving his/her functioning, gaining access to necessary services, and creating an environment that promotes recovery as identified in his/her Individual Recovery Plan (IRP). The focus of interventions include assisting the individual with: (1) developing natural supports to promote community integration, (2) identifying service needs, (3) referring and linking to services and resources identified through the service planning process, (4) coordinating services identified on the IRP to maximize service integration and minimize service gaps, and (5) ensuring continued adequacy of the IRP to meet his/her ongoing and changing needs. Contact must be made with the individual ≥2 times per month, at least one of which must be in-person, in a non-clinic setting.
Study NCT04612777 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intensive Case Management
Description: Intensive Case Management (ICM) is very similar to CM, but four in-person visits are required monthly. Additional contacts may be either face-to-face or via telephone, depending on the individual's needs. At least 60% of total contacts must be face-to-face with the individual, and at least 50% must be delivered in non-clinic/community-based settings. An ICM team includes nine professionals: a licensed clinician, four masters-level clinicians, two bachelors-level clinicians, and two paraprofessionals. The team's maximum case load is 200 in rural settings and 300 in urban settings (22-33 per team member).
Study NCT03640481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belumosudil (KD025)
Description: Belumosudil is an orally available Rho-associated protein kinase-2 (ROCK2) selective inhibitor.
Study NCT01406184 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Durham Connects
Description: The program consists of 4-7 intervention contacts, including 1) a hospital birthing visit when a staff member schedules an initial home visit; 2) 1-3 nurse home visits between 3-12 weeks of infant age to provide physical assessments for infant and mother, intervention and education, assessment of family-specific needs, and connections to matched community resources, as needed, to provide longer-term support; 3) 1-2 nurse contacts with community service providers to facilitate successful connections; and 4) a telephone follow-up one month after case closure to review community connection outcomes. With family consent, letters from the program reporting on the visit are also provided to also connect families to maternal and infant healthcare providers for ongoing support.
Study NCT00079586 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin
Description: Unfractionated Heparin per institutional practice
Study NCT00079586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: 1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
Study NCT03863327 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There will be no intervention as a part of this protocol.
Study NCT02741791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05
Description: AXS-05 taken daily for 6 weeks.
Study NCT02741791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Buproprion taken daily for 6 weeks.
Study NCT02944500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Study NCT02944500 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT00497848 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motivational interviewing
Description: An individual intervention building on the Motivational Interviewing by Miller and Rollnick. Several studies has proved effectiveness of this therapy form in improving drug compliance. Patients will be offered individual motivational therapy
Study NCT00497848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The System-Orientated Intervention
Description: Principles in this intervention come from Clinical Risk Managing and quality assurance. It focuses on daily problems in drug handling, including dropping out of drug therapy, by looking at the system as a whole.Some cases, where patients dropped out of drug therapy will be carefully analysed in order to identify week points in the system, and subsequently alter the instructions for drug therapy, information, reminders and so on.
Study NCT02169206 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Bilateral shoulder anteroposterior radiography
Description: 1. Patient standing with the tube in front and 105 cm far from the shoulder radiating perpendicular to the cassette in the back, both arms hanging aside the trunk in 0 degrees of arm abduction, 0 degrees of rotation and 0 degrees of extension with the thumb facing forward to obtain true bilateral shoulder anteroposterior view. Voltage and exposure time differs regarding each person's body mass.~2. In the same position, the patient only elevates the arm up to 90 degrees of abduction.
Study NCT02200237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EV71 with adjuvant aluminium phosphate
Description: Two arms, EV71 with aluminium phosphate
Study NCT02200237 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phosphate Buffer Saline with adjuvant aluminium phosphate
Study NCT01563367 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron isomaltoside 1000 (Monofer®)
Description: All subjects randomised to this group will receive 1000 mg iron isomaltoside 1000 as a single dose infusion administered over 15 minutes
Study NCT01563367 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Natriumklorid 9 mg/ml, Fresenius Kabi
Description: All subjects randomised to this group will receive an infusion of 100 ml 0.9% sodium chlorid administered over 15 min.
Study NCT02189655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid
Description: Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
Study NCT02954653 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PF-06747143
Description: PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.
Study NCT02954653 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06747143
Description: PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.
Study NCT02954653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: 100-200 mg/m2 continuous infusion for 7 days)
Study NCT02954653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: 60-90 mg/m2 daily for 3 days
Study NCT02954653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: 75 mg/m2 sub-cutaneous or intravenous for 7 days)
Study NCT02954653 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: 20 mg/m2 continuous intravenous infusion for 5 days in a 4-week schedule
Study NCT03722940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: Before induction of anesthesia; children in group M received an iv bolus dose of magnesium sulfate (Magnesium sulfate ampoule 1 gm/10 ml, Eipico, Egypt) 40 mg Kg-1 over 5 minutes followed by 15 mg Kg-1 h-1 ivi until the start of skin closure.
Study NCT03722940 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Na CL 0.9%
Description: Before induction of anesthesia; children in group C equivalent volumes of Na Cl 0.9% over the same period instead of magnesium sulphate.
Study NCT04323865 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: fetal heart rate variability
Description: No direct intervention, as the study is observational.
Study NCT02863081 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Administered to healthcare providers
Study NCT02863081 — intervention group
Intervention type: OTHER
Intervention: interview
Description: Administered to patients and LAR (i.e., interviews)
Study NCT02759887 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Actigraphy
Description: A non-invasive method of monitoring human rest and activity cycles. A small actigraph unit is worn to measure gross motor activity. The unit is usually worn on the wrist.
Study NCT03799406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Therapeutic trial of vitamin D supplementation during acute episode of bronchiolitis
Study NCT03799406 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo supplementation during acute episode of bronchiolitis
Study NCT00624559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib (Celebrex)
Description: Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet
Study NCT00624559 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pill taken twice per day on each day of the diet
Study NCT02854839 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MG4101
Description: MG4101 is ex vivo-expanded, allogeneic natural killer cells. MG4101 were manufactured from normal healthy donor who underwent lymphopheresis under good manufacturing practice (GMP) conditions.
Study NCT01213992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron isomaltoside 1000
Description: Single dose of 500 mg administered as a bolus undiluted over 2 min.
Study NCT01213992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron isomaltoside 1000
Description: Single dose of 1000 mg infused over 15 min. The infusion is diluted in 100mL 0,9% sodium chloride
Study NCT02169778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intermittent energy restricted diet
Study NCT02169778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous energy restricted diet
Study NCT04279756 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hip Mobilization with Movement, Self-Mobilization with Movement, Dynamic Stretch
Description: Participants receive either a therapist performed mobilization with movement, a self-mobilization with movement, or a dynamic stretch.
Study NCT01751581 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short Sleep
Description: Participants will be restricted in sleep and only allowed to sleep from 1 am to 5 am.
Study NCT01751581 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Habitual sleep
Description: Participants sleep 8 h/night throughout the study phase (from 11 pm to 7 am)
Study NCT01572311 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with dual-task gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise) while answering cognitively challenging questions.
Study NCT01572311 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Control
Description: Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise). This will not include any dual-task challenges.
Study NCT01520844 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: blood sampling
Description: blood sampling
Study NCT00556634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz given in a stepped dosage over 2 weeks (200 mg qd for 6 days plus placebo, 400 mg qd for 7 days plus placebo and 600 mg qd from day 14 forward)~OR~Efavirenz usual dosage (600 mg/day from the first day)
Study NCT00556634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efavirenz
Description: Efavirenz given in a stepped dosage over 2 weeks (200 mg qd for 6 days plus placebo, 400 mg qd for 7 days plus placebo and 600 mg qd from day 14 forward)~OR~Efavirenz usual dosage (600 mg/day from the first day)
Study NCT01384019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: distal protection and thrombus aspiration (The GuardWire Plus (Medtronic Inc.))
Description: The GuardWire Plus (Medtronic Inc.): distal balloon occlusion and proximal thrombus aspiration
Study NCT01384019 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: c-PCI
Description: conventional PCI without Guard wire
Study NCT00733083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0,1 mg/kg of oxycodone
Description: solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
Study NCT00733083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine 0,1 mg/kg
Description: solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
Study NCT00733083 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 0,5 mg/kg
Description: solution for injection, 0,5 mg/kg, one injection in the beginning of anesthesia
Study NCT00733083 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0,9%
Description: solution for injection one injection in the beginning of anesthesia
Study NCT01047332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Partially Covered Wallstent
Description: Partially covered wallstent
Study NCT01047332 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Uncovered Wallstent
Description: Uncovered wallstent
Study NCT02991716 — intervention group
Intervention type: OTHER
Intervention: recorded patients
Description: No intervention applied, only recording of cutaneous ECG signal from specific points on the torsi
Study NCT01381991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: i-scan
Description: For all the study procedures, Pentax EPKi processor and high-resolution adult video endoscopes (EG-2890i; Pentax, Japan) with push button switch from WL to i-scan were used. I-scan consist of three modes of image enhancement including SE, CE, ant TE. For SE and CE, switching among three enhancement levels (2+,3+,4+) is possible. Although SE and CE modes can allow detailed observation of subtle mucosal irregularities, noise increases as enhancement becomes more intense. In addition, TE is possible to switch p (pit pattern), v (vessel), b (Barrett), e (esophagus), g (stomach) and c (colo-rectum) mode.
Study NCT04288336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food Diary
Description: Ancillary studies
Study NCT04288336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preventative Dietary Intervention
Description: Follow intermittent fasting
Study NCT04288336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02971540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metamizol
Description: in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram with following intravenous infusion of 5 grams per day.
Study NCT02971540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: in group A patients will receive pre-emptive analgesia using intravenous infusion of tramadol in a single dose of 2 mg per hg of body weight with following intravenous infusion of 400 mg per day.
Study NCT02971540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: patients in group BF will receive local wound infiltration with a solution of 0,2% bupivacaine in a volume of 10 ml per segment of vertrebral columne.
Study NCT02295852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LOW-SODIUM LOW LIPID CALCIUM RICH DIET
Description: 1.Composition of the diet: Proteins 17%, Total lipids 28%, Saturated Fatty Acids 7%, Carbohydrates 54%, Fibers 42 g, Sodium 1377 mg, potassium 4067mg, Calcium 1211 mg
Study NCT02295852 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LOW-SODIUM LOW LIPID DIET
Description: 2. Composition of the diet: Proteins 17%, Total lipids 27%, Saturated Fatty Acids 7%, Carbohydrates 56%, Fibers 39 g, Sodium 1397 mg, potassium 3973 mg, Calcium 650 mg
Study NCT03787238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive vagus nerve stimulation
Description: non-invasive vagus nerve stimulation using the gammaCore Sapphire device
Study NCT02971540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: patients in group RF will receive local wound infiltration with a solution of 0,2% ropivacaine in a volume of 10 ml per segment of vertrebral columne.
Study NCT02971540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: control group
Description: patients will receive no pre-emptive analgesia. intraoperatively standard dose of fentanyl will be used.
Study NCT00842998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab or Lapatinib
Description: Trastuzumab: loading dose 8 mg/kg iv in 90 min.followed by weekly doses of 2 mg/kg Lapatinib: 1500 mg/die orally
Study NCT02879994 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02879994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT01029171 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based balance and strength retraining exercise program.
Description: A 12-month home-based balance and strength restraining program delivered by a physical therapist
Study NCT01029171 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control; usual care
Description: Usual care as prescribed by geriatrician.
Study NCT02753387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: 4 mouthwashes during 30 seconds with Eludril Perio 10 ml and 1 application after intubation with Eludril Perio
Study NCT02753387 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9 %
Description: 4 mouthwashes during 30 seconds with NaCl 0.9 % 10 ml and 1 application after intubation with NaCl 0.9 %
Study NCT02519634 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Super-Mini Percutaneous Nephrolithotomy
Description: Patients undergo Super-Mini Percutaneous Nephrolithotomy
Study NCT02519634 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Retrograde Intrarenal Surgery
Description: Patients undergo Retrograde Intrarenal Surgery
Study NCT01255410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10^6 PFU rHMPV-Pa vaccine
Description: Single dose of 10\^6 PFU rHMPV-Pa vaccine delivered intranasally
Study NCT01255410 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10^5 PFU rHMPV-Pa vaccine
Description: Single dose of 10\^5 PFU rHMPV-Pa vaccine delivered intranasally
Study NCT01255410 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Vaccine
Description: Single dose of placebo vaccine delivered intranasally
Study NCT00945204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intermediate care clinics (ICCs)
Description: The ICCs will be community based. Their aim is to support primary care, particularly smaller practices that have the most difficulty achieving good control. They will comprise a multidisciplinary team, and be led by specialist nurses who will place an emphasis on education and self management. Medical care will be provided by a diabetologist. The ICC will work closely with hospital based specialist teams and community services including podiatry and dietetics. Team members will work to local guidelines, adapted from national evidence based guidelines. Guidelines for referral to the ICCs will be common across all sites, and will include people with poorly controlled type 2 diabetes and those with poorly controlled cardiovascular risk factors.
Study NCT02760472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SMOFlipid
Description: Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
Study NCT02760472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clinoleic
Description: Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
Study NCT03987659 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irrigation protocols that promote release of dECMs
Description: Irrigation protocols that promote release of dECMs
Study NCT03987659 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Irrigation protocols
Description: Conventional Irrigation protocols